Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the STORM and STOMP clinical trials in patients with multiple myeloma.
Sundar Jagannath, MDDS
Advertisement
Articles by Sundar Jagannath, MDDS
Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the mechanism of action of selinexor for the treatment of multiple myeloma.
Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses a first in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
An Overview of a Study of bb2121 in Multiple MyelomaPublished: June 30th 2017 | Updated:
- Mechanism of Action of Selinexor for the Treatment of Multiple Myeloma
Published: July 18th 2017 | Updated:
Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple MyelomaPublished: September 12th 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
